Get the app
US › Healthcare

Akebia Ther (AKBA)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$0.67-3.74%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$49.1M
Revenue YoY
-21.4%
Net profit
$-8.9M
Profit YoY
-3706.5%
EPS
$-0.02
EPS estimate
$-0.03
Net margin
-18.1%

EPS came in at -0.02 against a street estimate of -0.03 — a beat of 33.3%.

Key statistics

Market cap
$185.7M
Forward P/E
28.7
P/B
10.33
Book value
$0.09
EPS (TTM)
$-0.12
52-week high
$3.20
52-week low
$0.67
50-day MA
$0.89
200-day MA
$1.19
Beta
0.18

Analyst view

Analysts rate Akebia Ther a strong buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $3.92.

Shareholding

Insiders
1.98%
Institutions
40.76%

Largest institutional holders

FundStake
BlackRock Inc7.21%
Vanguard Capital Management, LLC4.09%
AQR Capital Management LLC3.30%
Geode Capital Management, LLC2.43%
State Street Corp1.95%
Jacobs Levy Equity Management, Inc.1.54%
Acadian Asset Management LLC1.45%
Nantahala Capital Management, LLC1.44%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Akebia Ther — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-18.